Clinical First-in-Human Single-Dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-Center, Phase I, Open-Label, i.v. Infusion Study.

Trial Profile

Clinical First-in-Human Single-Dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-Center, Phase I, Open-Label, i.v. Infusion Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Claudiximab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Ganymed Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 31 Aug 2017 According to a Astellas Pharma media release, new data from this study will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 04 Aug 2010 Results reported in a Ganymed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top